This presentation considered three potential changes that the Commission could recommend to strengthen Medicaid’s drug rebate program:
- correcting the line extension drug formula,
- excluding authorized generics from the average manufacturer price of the brand drug, and
- strengthening federal oversight.
Discussion focused on the merits of these recommendations and their effects on state and federal budgets, drug manufacturers, and beneficiaries.
Publication Type: Presentations